BARCELONA—Ultrahypofractionated radiation (U-HF) delivered in only seven fractions (each triple the usual dose) in two and a half weeks was just as effective for treating intermediate-risk prostate cancer—with no greater toxicity—as a standard protocol with 39 fractions over eight-weeks in findings from the phase 3 Scandinavian HYPO-RT-PC study reported at the 2018 European Society For Radiotherapy and Oncology (ESTRO 37) annual conference. http://www.mynewsdesk.com/se/umea_universitet/documents/abstract-prostatastudie-77805
Anders Widmark MD PhD, Professor of Oncology and Senior Consultant in the Department of Radiation Oncology and the Umeå University Hospital Cancer Centre in Umeå, North Sweden talks with the Audio Journal of Oncology about why they undertook their study and about the clinical implications of their findings.
